Likely impact of pre-exposure prophylaxis on HIV epidemics among men who have sex with men

被引:8
作者
Zablotska, Iryna B. [1 ]
机构
[1] UNSW Australia, Kirby Inst, Sydney, NSW 2052, Australia
关键词
combination prevention; effect; HIV; AIDS; implementation; mathematical model; pre-exposure prophylaxis (PrEP); review; COST-EFFECTIVENESS; UNITED-STATES; PREVENTION;
D O I
10.1071/SH16153
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Rapid developments in the field of HIV pre-exposure prophylaxis (PrEP) with antiretrovirals offer a promise to bring HIV transmission among gay and other men who have sex with men (MSM) to zero by 2030. This review evaluates studies, which modelled the impact of PrEP on HIV diagnoses, and discusses the progress towards PrEP implementation. Studies in English, conducted after 2010 among MSM in countries of the Organization for Economic Cooperation and Development (OECD) were reviewed. Six modelling studies were included, three of which had been conducted outside the US. None of the published models showed that PrEP alone can reduce HIV diagnoses to zero and eliminate HIV transmission by 2030. However, PrEP in combination with other biomedical interventions can reduce HIV diagnoses on the population level by similar to 95%. Other upcoming biomedical prevention strategies may strengthen combination prevention. Access to PrEP remains limited, even in the OECD countries. Modelling studies can assist governments with decision-making about PrEP implementation and add urgency to the implementation of PrEP. More work is needed on modelling of the impact of PrEP on HIV diagnoses trends outside the US where PrEP implementation is in its early stages.
引用
收藏
页码:97 / 105
页数:9
相关论文
共 35 条
  • [1] Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with Men
    Anderson, Peter L.
    Glidden, David V.
    Liu, Albert
    Buchbinder, Susan
    Lama, Javier R.
    Vicente Guanira, Juan
    McMahan, Vanessa
    Bushman, Lane R.
    Casapia, Martin
    Montoya-Herrera, Orlando
    Veloso, Valdilea G.
    Mayer, Kenneth H.
    Chariyalertsak, Suwat
    Schechter, Mauro
    Bekker, Linda-Gail
    Kallas, Esper Georges
    Grant, Robert M.
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2012, 4 (151)
  • [2] Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection
    Anderson, Peter L.
    Kiser, Jennifer J.
    Gardner, Edward M.
    Rower, Joseph E.
    Meditz, Amie
    Grant, Robert M.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2011, 66 (02) : 240 - 250
  • [3] PrEP: why are we waiting?
    不详
    [J]. LANCET HIV, 2015, 2 (10): : E401 - E401
  • [4] NHS England should reconsider PrEP decision
    不详
    [J]. LANCET HIV, 2016, 3 (05): : E191 - E191
  • [5] [Anonymous], AIDS NUMB
  • [6] [Anonymous], 2015, GUID VERS 8 0
  • [7] [Anonymous], 2022, FACT SHEET 8 IMM
  • [8] [Anonymous], 2012, ANN INTERN MED, DOI DOI 10.1059/0003-4819-156-8-201204170-00001
  • [9] [Anonymous], PRESCR MED NEW EXT U
  • [10] Sex Role Segregation and Mixing among Men Who Have Sex with Men: Implications for Biomedical HIV Prevention Interventions
    Armbruster, Benjamin
    Roy, Sourya
    Kapur, Abhinav
    Schneider, John A.
    [J]. PLOS ONE, 2013, 8 (08):